Clinical Trial Update: The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating HLX208 (BRAF V600E inhibitor) in combination with cetuximab for metastatic colorectal cancer with BRAF V600E mutation after first-line …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• HLX208

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: CRC | Phase 2 | Status: UNKNOWN